Drug Information

Drug General Information
Drug ID
D0K9BV
Former ID
DIB004744
Drug Name
TVB-2640
Indication Advanced solid tumor [ICD9: 140-199; ICD10:C00-C75, C7A, C7B] Phase 1 [524890]
Company
3-v biosciences
Target and Pathway
Target(s) Fatty acid synthase Target Info Inhibitor [544409]
BioCyc Pathway Fatty acid biosynthesis initiation
Fatty acid elongation -- saturated
Palmitate biosynthesis
KEGG Pathway Fatty acid biosynthesis
Metabolic pathways
Fatty acid metabolism
AMPK signaling pathway
Insulin signaling pathway
Pathway Interaction Database p73 transcription factor network
Validated transcriptional targets of deltaNp63 isoforms
PathWhiz Pathway Fatty Acid Biosynthesis
Reactome ChREBP activates metabolic gene expression
Activation of gene expression by SREBF (SREBP)
Fatty Acyl-CoA Biosynthesis
WikiPathways Fatty Acid Biosynthesis
Nuclear Receptors Meta-Pathway
Liver X Receptor Pathway
Activation of Gene Expression by SREBP (SREBF)
SREBF and miR33 in cholesterol and lipid homeostasis
SREBP signalling
Metabolism of water-soluble vitamins and cofactors
Integration of energy metabolism
Fatty acid, triacylglycerol, and ketone body metabolism
AMPK Signaling
References
Ref 524890ClinicalTrials.gov (NCT02223247) A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors. U.S. National Institutes of Health.
Ref 544409Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.